Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-C0902 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BG-C0902, a putative antibody-drug conjugate (ADC) targeting EGFR and MET (Dec 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-C0902 | BGC0902|BG C0902 | EGFR Antibody 74 MET Antibody 39 | Limited information is currently available on BG-C0902, a putative antibody-drug conjugate (ADC) targeting EGFR and MET (Dec 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07181681 | Phase I | BG-C0902 | A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 1 |